2023
Kinvig, H., Rajoli, R. K. R., Pertinez, H., Vora, L. K., Volpe-Zanutto, F., Donnelly, R. F., . . . Owen, A. (2023). Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.. Pharmaceutics, 15(12), 2709. doi:10.3390/pharmaceutics15122709DOI: 10.3390/pharmaceutics15122709
Box, H. J., Sharp, J., Pennington, S. H., Kijak, E., Tatham, L., Caygill, C. H., . . . Owen, A. (2023). Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.. The Journal of antimicrobial chemotherapy, dkad362. doi:10.1093/jac/dkad362DOI: 10.1093/jac/dkad362
Gallardo-Toledo, E., Neary, M., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters.. Viruses, 15(11), 2161. doi:10.3390/v15112161DOI: 10.3390/v15112161
Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. VIRUSES-BASEL, 15(8). doi:10.3390/v15081744DOI: 10.3390/v15081744
Neary, M., Arshad, U., Tatham, L., Pertinez, H., Box, H., Rajoli, R. K. R., . . . Owen, A. (2023). Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1228. doi:10.1016/j.jchromb.2023.123823DOI: 10.1016/j.jchromb.2023.123823
Chang, Y. S., Li, S. -Y., Pertinez, H., Betoudji, F., Lee, J., Rannard, S. P., . . . Ammerman, N. C. (2023). Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 67(7). doi:10.1128/aac.00481-23DOI: 10.1128/aac.00481-23
Curley, P., Hobson, J. J., Liptrott, N. J., Makarov, E., Al-Khouja, A., Tatham, L., . . . Owen, A. (2023). Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.. Pharmaceutics, 15(7), 1835. doi:10.3390/pharmaceutics15071835DOI: 10.3390/pharmaceutics15071835
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., . . . Sampaziotis, F. (2023). FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. NATURE, 615(7950), 134-+. doi:10.1038/s41586-022-05594-0DOI: 10.1038/s41586-022-05594-0
2022
Sibley, L., White, A. D., Sarfas, C., Gullick, J., Gleeson, F., Lanni, F., . . . Sharpe, S. (2022). Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of <i>Mycobacterium tuberculosis</i> Infection. PHARMACEUTICS, 14(12). doi:10.3390/pharmaceutics14122666DOI: 10.3390/pharmaceutics14122666
McCallum, A. D., Pertinez, H. E., Chirambo, A. P., Sheha, I., Chasweka, M., Malamba, R., . . . Mwandumba, H. C. (2022). High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis. CLINICAL INFECTIOUS DISEASES, 75(9), 1520-1528. doi:10.1093/cid/ciac228DOI: 10.1093/cid/ciac228
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., . . . Fletcher, T. E. (2022). An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(3), 585-594. doi:10.1002/cpt.2463DOI: 10.1002/cpt.2463
2021
Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318DOI: 10.1093/jac/dkab318
McCallum, A. D., Pertinez, H. E., Else, L. J., Dilly-Penchala, S., Chirambo, A. P., Sheha, I., . . . Mwandumba, H. C. (2021). Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis. CLINICAL INFECTIOUS DISEASES, 73(9), E3365-E3373. doi:10.1093/cid/ciaa1265DOI: 10.1093/cid/ciaa1265
Dickinson, L., Walimbwa, S., Singh, Y., Kaboggoza, J., Kintu, K., Sihlangu, M., . . . Orrell, C. (2021). Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. CLINICAL INFECTIOUS DISEASES, 73(5), E1200-E1207. doi:10.1093/cid/ciaa1861DOI: 10.1093/cid/ciaa1861
Pertinez, H., Rajoli, R. K. R., Khoo, S. H., & Owen, A. (2021). Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2121-2128. doi:10.1093/jac/dkab135DOI: 10.1093/jac/dkab135
Yip, V. L. M., Pertinez, H., Meng, X., Maggs, J. L., Carr, D. F., Park, B. K., . . . Pirmohamed, M. (2021). Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(6), 2572-2588. doi:10.1111/bcp.14667DOI: 10.1111/bcp.14667
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309gDOI: 10.1039/d1nr00309g
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619DOI: 10.1111/bcp.14619
2020
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909DOI: 10.1002/cpt.1909
2019
Hendon-Dunn, C. L., Pertinez, H., Marriott, A. A. N., Hatch, K. A., Allnutt, J. C., Davies, G., & Bacon, J. (2019). Regrowth of <i>Mycobacterium</i> <i>tuberculosis</i> Populations Exposed to Antibiotic Combinations Is Due to the Presence of Isoniazid and Not Bacterial Growth Rate. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(12). doi:10.1128/AAC.00570-19DOI: 10.1128/AAC.00570-19
Hu, Y., Pertinez, H., Liu, Y., Davies, G., & Coates, A. (2019). Bedaquiline kills persistent <i>Mycobacterium tuberculosis</i> with no disease relapse: an <i>in vivo</i> model of a potential cure. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1627-1633. doi:10.1093/jac/dkz052DOI: 10.1093/jac/dkz052
2018
Velasquez, G. E., Brooks, M. B., Coit, J. M., Pertinez, H., Vasquez, D. V., Garavito, E. S., . . . Mitnick, C. D. (2018). Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 198(5), 657-666. doi:10.1164/rccm.201712-2524OCDOI: 10.1164/rccm.201712-2524OC
Stott, K. E., Pertinez, H., Sturkenboom, M. G. G., Boeree, M. J., Aarnoutse, R., Ramachandran, G., . . . Davies, G. (2018). Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(9), 2305-2313. doi:10.1093/jac/dky152DOI: 10.1093/jac/dky152
Millard, J., Pertinez, H., Bonnett, L., Hodel, E. M., Dartois, V., Johnson, J. L., . . . Sloan, D. J. (2018). Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(7), 1755-1762. doi:10.1093/jac/dky096DOI: 10.1093/jac/dky096
Liu, Y., Pertinez, H., Davies, G. R., Gillespie, S. H., Coates, A. R., & Hua, Y. (2018). Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent<i> Mycobacterium tuberculosis</i> in the Cornell Mouse Model. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00190-18DOI: 10.1128/AAC.00190-18
Millard, J., Pertinez, H., Bonnett, L. J., Hodel, E., Dartois, V., Johnson, J. L., . . . Sloan, D. (2018). Linezolid pharmacokinetics in multidrug resistant tuberculosis (MDR TB): a systematic review, meta-analysis and Monte Carlo simulation. Journal of Antimicrobial Chemotherapy.
Liu, Y., Pertinez, H., Ortega-Muro, F., Alameda-Martin, L., Harrison, T., Davies, G., . . . Hu, Y. (2018). Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(3), 724-731. doi:10.1093/jac/dkx467DOI: 10.1093/jac/dkx467
2017
de Knegt, G. J., Dickinson, L., Pertinez, H., Evangelopoulos, D., McHugh, T. D., Bakker-Woudenberg, I. A. J. M., . . . de Steenwinkel, J. E. M. (2017). Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model. TUBERCULOSIS, 105, 113-118. doi:10.1016/j.tube.2017.05.002DOI: 10.1016/j.tube.2017.05.002
A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days (Journal article)
Wootton, D. G., Dickinson, L., Pertinez, H., Court, J., Eneje, O., Keogan, L., . . . Diggle, P. J. (2017). A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days. European Respiratory Journal, 49(6). doi:10.1183/13993003.02170-2016DOI: 10.1183/13993003.02170-2016
2016
A combination of clinical and genetic covariates significantly influence the metabolism of carbamazepine: potential implications for carbamazepine hypersensitivity (Presentation material)
Yip, V. L. M., Meng, X., Maggs, J. L., Pertinez, H., Carr, D. F., Marson, A. G., . . . Pirmohamed, M. (2016). A combination of clinical and genetic covariates significantly influence the metabolism of carbamazepine: potential implications for carbamazepine hypersensitivity. London, UK.
Hu, Y., Pertinez, H., Ortega-Muro, F., Alameda-Martin, L., Liu, Y., Schipani, A., . . . Coates, A. (2016). Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(8), 4778-4785. doi:10.1128/AAC.02548-15DOI: 10.1128/AAC.02548-15
Schipani, A., Pertinez, H., Mlota, R., Molyneux, E., Lopez, N., Dzinjalamala, F. K., . . . Davies, G. (2016). A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 81(4), 679-687. doi:10.1111/bcp.12848DOI: 10.1111/bcp.12848
2013
A physiologically based pharmacokinetic model for strontium exposure in rat. (Journal article)
Pertinez, H., Chenel, M., & Aarons, L. (2013). A physiologically based pharmacokinetic model for strontium exposure in rat.. Pharmaceutical research, 30(6), 1536-1552. doi:10.1007/s11095-013-0991-xDOI: 10.1007/s11095-013-0991-x